NASDAQ:SBTX Silverback Therapeutics (SBTX) Stock Price, News & Analysis $10.98 -0.21 (-1.88%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$10.93▼$11.3550-Day Range$7.65▼$11.6652-Week Range$2.80▼$8.97Volume593,931 shsAverage Volume337,931 shsMarket Capitalization$395.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrendsStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends Get Silverback Therapeutics alerts: Email Address Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about About Silverback Therapeutics Stock (NASDAQ:SBTX)Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Read More SBTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SBTX Stock News HeadlinesMay 11, 2023 | uk.investing.comARS Pharmaceuticals Inc (SPRY)January 24, 2023 | seekingalpha.comSPRY ARS Pharmaceuticals, Inc.July 26, 2024 | WealthPress (Ad)New trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.November 22, 2022 | 247wallst.comARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After MergerNovember 18, 2022 | nasdaq.comDr. Sarina Tanimoto Discloses Position in SBTX / Silverback TherapeuticsNovember 10, 2022 | finance.yahoo.comARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisNovember 8, 2022 | finance.yahoo.comARS Pharmaceuticals Closes Merger with Silverback TherapeuticsOctober 28, 2022 | markets.businessinsider.comSilverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic ReactionsJuly 26, 2024 | WealthPress (Ad)New trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.October 21, 2022 | finance.yahoo.comSilverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including AnaphylaxisSeptember 17, 2022 | markets.businessinsider.comINVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBTSeptember 15, 2022 | seekingalpha.comSBTX Silverback Therapeutics, Inc.September 6, 2022 | markets.businessinsider.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBTAugust 23, 2022 | markets.businessinsider.comSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZYAugust 17, 2022 | apnews.comSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, HNGR, SBTXAugust 11, 2022 | apnews.comSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates IEA, BBQ, SBTXJuly 30, 2022 | morningstar.comSHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing InvestigationsJuly 28, 2022 | apnews.comINVESTIGATION ALERT: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZYSee More Headlines Receive SBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silverback Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SBTX CUSIPN/A CIK1671858 Webwww.silverbacktx.com Phone206 456 2900FaxN/AEmployees83Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,480,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.62% Return on Assets-28.20% Debt Debt-to-Equity RatioN/A Current Ratio67.87 Quick Ratio67.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.41 per share Price / Book1.51Miscellaneous Outstanding Shares36,058,000Free Float23,654,000Market Cap$403.49 million OptionableNot Optionable Beta0.60 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Peter A. Thompson FACP (Age 62)M.D., Co-Founder & Chairman of Directors Comp: $5.12kMr. Jeffrey C. Pepe J.D.Ph.D., Interim CEO, Gen. Counsel & Corp. Sec.Mr. Russ Hawkinson (Age 63)Sr. VP of Fin., Interim CFO, Principal Financial Officer & Principal Accounting Officer Mr. Miguel Arcinas M.B.A.VP of Corp. Devel. & Investor RelationsJen MoreDirector of HRMs. Sue HamkeSr. VP of Clinical OperationsMr. Dario Gobunquin CPASr. Director of Accounting & ControllerMore ExecutivesKey CompetitorsNurix TherapeuticsNASDAQ:NRIXDynavax TechnologiesNASDAQ:DVAXDay One BiopharmaceuticalsNASDAQ:DAWNANI PharmaceuticalsNASDAQ:ANIPArcus BiosciencesNYSE:RCUSView All Competitors SBTX Stock Analysis - Frequently Asked Questions How have SBTX shares performed this year? Silverback Therapeutics' stock was trading at $5.48 at the beginning of the year. Since then, SBTX stock has increased by 100.4% and is now trading at $10.98. View the best growth stocks for 2024 here. How were Silverback Therapeutics' earnings last quarter? Silverback Therapeutics, Inc. (NASDAQ:SBTX) posted its earnings results on Wednesday, November, 10th. The company reported ($0.65) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.65). When did Silverback Therapeutics IPO? Silverback Therapeutics (SBTX) raised $126 million in an IPO on Friday, December 4th 2020. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, SVB Leerink and Stifel served as the underwriters for the IPO and H.C. Wainwright was co-manager. How do I buy shares of Silverback Therapeutics? Shares of SBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SBTX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silverback Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Silverback Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.